Bumetanide

Generic Name: Bumetanide

Brand Names: Bumex, Burinex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₂O_₅S

CAS Number: 28395-03-1

Unique Ingredient Identifier: 0Y2S3XUQ5H

Background: Bumetanide is a sulfamyl diuretic.

Indication: For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.

Associated Conditions: Edema

Clinical Trials

Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

Phase 2

Conditions: Parkinson Disease

Interventions: Drug: Bumetanide white, oblong, scored tablet
Drug: Placebo white, oblong, scored tablet

First Posted Date: 2019-04-02

Last Posted Date: 2019-07-23

Lead Sponsor: B&A Therapeutics

Target Recruit Count: 40

Registration Number: NCT03899324

Locations: 🇫🇷
Chu Nantes, Nantes, France

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Phase 3

Terminated

Conditions: Autism Spectrum Disorder (ASD)

Interventions: Drug: BUMETANIDE (S95008) for week 0 - 26
Drug: PLACEBO for week 0 - 26
Drug: Open-Label BUMETANIDE (S95008) for weeks 26 - 52

First Posted Date: 2018-10-23

Last Posted Date: 2023-06-05

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 211

Registration Number: NCT03715153

Locations: 🇫🇷
Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France
🇵🇱
"Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Poland
🇭🇺
Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary

and more 47 locations

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Phase 3

Terminated

Conditions: Autism Spectrum Disorder (ASD)

Interventions: Drug: Bumetanide Oral Solution
Drug: Placebo

First Posted Date: 2018-10-23

Last Posted Date: 2024-07-25

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 211

Registration Number: NCT03715166

Locations: 🇮🇹
Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy
🇮🇹
Programma Interdipartimentale "Autismo 0-90" A.O.U. Policlinico "Gaetano Martino", Messina, Sicilia, Italy
🇮🇹
U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy

and more 42 locations

Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure

Phase 4

Conditions: Heart Failure
Congestive Heart Failure

Interventions: Drug: Bumetanide 1 MG

First Posted Date: 2018-10-17

Last Posted Date: 2018-10-17

Lead Sponsor: Centro en Insuficiencia Cardiaca, Mexico

Target Recruit Count: 40

Registration Number: NCT03709160

Locations: 🇲🇽
Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia, Mexico City, Mexico

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

Phase 2

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Placebo
Drug: Bumetanide

First Posted Date: 2017-05-17

Last Posted Date: 2021-03-01

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 120

Registration Number: NCT03156153

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Phase 1

Active, not recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Procedure: Hepatic artery embolization (HAE)
Drug: Bumetanide

First Posted Date: 2017-04-11

Last Posted Date: 2025-05-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03107416

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States

and more 2 locations

Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology

Phase 2

Withdrawn

Conditions: Autistic Disorder

Interventions: Drug: Placebo
Drug: Bumetanide

First Posted Date: 2016-10-28

Last Posted Date: 2021-06-02

Lead Sponsor: University Hospital, Limoges

Registration Number: NCT02947880

Diuretic/Cool Dialysate Trial

Not Applicable

Terminated

Conditions: Chronic Kidney Insufficiency

Interventions: Drug: Bumetanide
Other: Cool Dialysate

First Posted Date: 2015-11-01

Last Posted Date: 2024-01-11

Lead Sponsor: University of New Mexico

Target Recruit Count: 11

Registration Number: NCT02593526

Locations: 🇺🇸
Dialysis Clinic Inc. - Indian School, Albuquerque, New Mexico, United States

Bumetanide in Hypokalaemic Periodic Paralysis

Phase 2

Terminated

Conditions: Hypokalemic Periodic Paralysis

First Posted Date: 2015-10-21

Last Posted Date: 2018-02-07

Lead Sponsor: University College, London

Target Recruit Count: 12

Registration Number: NCT02582476

Locations: 🇬🇧
MRC Centre for Neuromuscular Disorders, London, United Kingdom

NEMO1:NEonatal Seizure Using Medication Off-patent

Phase 1

Completed

Conditions: Neonatal Seizures

Interventions: Drug: Bumetanide

First Posted Date: 2011-09-14

Last Posted Date: 2015-09-14

Lead Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust

Target Recruit Count: 14

Registration Number: NCT01434225

Locations: 🇮🇪
Cork University Maternity Hospital, Cork, Ireland
🇳🇱
Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy